Pittsburgh, PANCT07262138Now EnrollingIRB Ready

Early Stage Estrogen Receptor (ER) Positive Breast Cancer Clinical Trial in Pittsburgh, PA

Access cutting-edge early stage estrogen receptor (er) positive breast cancer treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by University of Pittsburgh

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access early stage estrogen receptor (er) positive breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related early stage estrogen receptor (er) positive breast cancer treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this early stage estrogen receptor (er) positive breast cancer clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Early Stage Estrogen Receptor (ER) Positive Breast Cancer Study in Pittsburgh

ACTIVE is a prospective, single-arm, phase I/IIa study examining an active surveillance strategy for small, screen-detected, luminal breast cancer. Patients aged 70 or older with clinical stage I ER+/HER2- breast cancer are eligible. The goal of this clinical trial is to learn if an active surveillance strategy (serial imaging rather than therapeutic intervention) is a safe approach to monitor small breast cancers. The main question to answer is the proportion of participants who experience tumor progression by 12 months.

Sponsor: University of Pittsburgh

Who Can Participate

Inclusion Criteria

Women aged 70 years or older with a diagnosis of invasive breast cancer who have not undergone surgical resection of the primary invasive tumor and/or axillary lymph nodes, have not undertaken any systemic therapy, and have not received radiation therapy as a treatment for this diagnosis. Patients with invasive cancer that is identified after excisional biopsy for atypia are included.
Tumors must have been identified through mammographic screening.
Tumor is less than or equal to 2cm (T1a through T1c) in maximum dimension based on diagnostic ultrasound, or if not visible on ultrasound, then on mammogram. Must have clinically and radiographically node negative disease. Inclusion criteria for different tumor sizes is as follows:
cT1a or cT1b (≤ 1cm): Nottingham Grade I or II allowed entry.
cT1c (\>1-2cm): only Nottingham Grade I allowed entry.
Breast cancer must be ER positive and HER2 negative according to the definition below, as assessed by local pathology.
ER is considered positive if there are ≥ 60% positive tumor nuclei in the samples.
HER2 negativity is defined per the current ASCO/CAP Clinical Practice Guideline.
Patients with cognitive impairment are eligible provided that a legal surrogate is able to sign informed consent for study participation.
Archival tissue will be submitted for all participants. Tissue must be confirmed available prior to registration.

Exclusion Criteria

Prior anti-cancer therapy (e.g., endocrine therapy, chemotherapy, radiation therapy, or investigational therapy) for the current breast cancer diagnosis.
Current breast cancer diagnosis that is deemed a recurrence, at the discretion of the treating investigator.
Multifocal or multicentric disease.
Patients with a history of contralateral DCIS, or ipsilateral or contralateral LCIS are not eligible. Patients with a history of any ipsilateral breast radiation are not eligible.
Diagnosis of inflammatory breast cancer (T4d).
Male breast cancer.
Any concurrent severe and uncontrolled medical condition that, in the treating clinician's opinion, would pose unacceptable safety risks or compromise compliance with the protocol. Such conditions could include: impairment of gastrointestinal tract function or gastrointestinal disease that may significantly alter the absorption of oral medications (uncontrolled Crohn disease or ulcerative colitis, uncontrolled chronic nausea, vomiting diarrhea, malabsorption, or small bowel resection); severe liver impairment (Child-Pugh Class C).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT07262138) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Early Stage Estrogen Receptor (ER) Positive Breast Cancer Treatment Options in Pittsburgh, PA

If you're searching for early stage estrogen receptor (er) positive breast cancer treatment options in Pittsburgh, PA, this clinical trial (NCT07262138) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced early stage estrogen receptor (er) positive breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all early stage estrogen receptor (er) positive breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Pittsburgh, PA

See all breast cancer clinical trials recruiting in Pittsburgh — not just this study.

Browse Breast Cancer Trials in Pittsburgh →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA